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We have derived a versatile gene-based test for genome-wide association studies (GWAS). Our approach, called VEGAS (versatile gene-
based association study), is applicable to all GWAS designs, including family-based GWAS, meta-analyses of GWAS on the basis of
summary data, and DNA-pooling-based GWAS, where existing approaches based on permutation are not possible, as well as singleton
data, where they are. The test incorporates information from a full set of markers (or a deﬁned subset) within a gene and accounts for
linkage disequilibrium between markers by using simulations from the multivariate normal distribution. We show that for an associa-
tion study using singletons, our approach produces results equivalent to those obtained via permutation in a fraction of the computation
time. We demonstrate proof-of-principle by using the gene-based test to replicate several genes known to be associated on the basis of
results from a family-based GWAS for height in 11,536 individuals and a DNA-pooling-based GWAS for melanoma in ~1300 cases and
controls. Our method has the potential to identify novel associated genes; provide a basis for selecting SNPs for replication; and be
directly used in network (pathway) approaches that require per-gene association test statistics. We have implemented the approach
in both an easy-to-use web interface, which only requires the uploading of markers with their association p-values, and a separate down-
loadable application.Gene-based tests for association are increasingly being seen
as a useful complement to genome-wide association
studies (GWAS).1 A gene-based approach considers associ-
ation between a trait and all markers (usually SNPs) within
a gene rather than eachmarker individually. Depending on
the underlying genetic architecture, gene-based ap-
proaches can be more powerful than traditional indi-
vidual-SNP-based GWAS. For example, if a gene contains
more than one causative variant, then several SNPs within
that gene might show marginal levels of signiﬁcance that
are often indistinguishable from random noise in the
initial GWAS results. By combining the effects of all SNPs
in a gene into a test-statistic and correcting for linkage
disequilibrium (LD), the gene-based test might be able to
detect these effects. Gene-based tests are also ideally suited
for network (or pathway) approaches to interpreting the
ﬁndings from GWAS.2–7 These approaches are necessarily
gene centric and require a measure of the relative impor-
tance of each gene to the phenotype of interest. The
gene-based approach also reduces the multiple-testing
problem of GWAS by only considering statistical tests for
~20,000 genes per genome as opposed to testing more
than half a million SNPs in a typical GWAS.
Ideally, a gene-based test statistic can be obtained with
permutations, where LD structure and other possible con-
founding factors, such as gene size, will be accounted for.
Computing a gene-based test for basic GWAS designs via
permutations is conceptually simple and is currently im-
plemented as the ‘‘set-based test’’ in the PLINK software
package8; however, heavy computational requirements1Genetics and Population Health Division, Queensland Institute of Medical Re
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The Ahave restricted this method from being adopted on
a genome-wide scale. Other gene-based tests, such as those
based on genetic distances9 or entropy,10 are often also
restricted to situations where individual genotype infor-
mation is available or to speciﬁc GWAS designs (usually
case-control designs). There are several important situa-
tions in which permutations or existing methods cannot
be used; these include family-based GWAS, GWAS meta-
analyses based on summary data, and DNA-pooling-based
GWAS. In contrast, our approach, called VEGAS (versatile
gene-based association study), only requires individual
marker p values in order to allow computation of a gene-
based p value, and it can be applied to virtually any associ-
ation study design. The method tests the evidence for asso-
ciation on a per-gene basis by summarizing either the full
set of markers (typically SNPs) in the gene or a subset of the
most signiﬁcant markers (for example, the 10% most
signiﬁcant SNPs). For some genes, an approach consid-
ering all the markers might be the most powerful; for
others, focusing on just the most associated markers might
be apt. The true underlying genetic architecture is seldom
known in advance. The default gene-based test in our
implementation and in the following examples uses the
full set of markers in the gene. Our approach takes account
of LD betweenmarkers in a gene by using simulation based
on the LD structure of a set of reference individuals
from a HapMap phase 2 population (CEU [Utah residents
with ancestry from northern and western Europe]; CHB
and JPT [Han Chinese in Beijing, China and Japanese in
Tokyo, Japan]; or YRI [Yoruba in Ibadan, Nigeria]), whichsearch, Brisbane, Queensland 4006, Australia; 2Integrated Cancer Genomics
5028, USA; 3Australian Melanoma Family Study. List of participants and
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provides approximately ~2.1 million autosomal SNPs,11 or
a custom set of individuals if genotype information is
available.
Our method assigns SNPs to each of 17,787 autosomal
genes according to positions on theUCSCGenomeBrowser
hg18 assembly. In order to capture regulatory regions
and SNPs in LD, we deﬁne gene boundaries in this case
as 5 50 kb of 50 and 30 UTRs. Then, for a given gene with
n SNPs, association p values are ﬁrst converted to upper-
tail chi-squared statistics with one degree of freedom (df).
The gene-based test statistic is then the sum of all (or
a pre-deﬁned subset) of the chi-squared1df statisticswithin
that gene. If the SNPs are in perfect linkage equilibrium, the
test statistic will have a chi-squared distribution with n
degrees of freedom under the null hypothesis. Because
this is unlikely to be the case, however, the true null distri-
bution given the LD structure (and hence p values that
correlate accordingly) will need to be taken into account.
Ideally, one would achieve this by performing a large
number of permutations; however, this is very computa-
tionally intensive, requires individual genotype informa-
tion, and assumes that individuals are unrelated. Instead,
our Monte Carlo approach makes use of simulations from
the multivariate normal distribution and is both much
faster and agnostic regarding the GWAS design.
For a gene with n SNPs, we simulate an n-element multi-
variate normally distributed vector with mean 0 and vari-
ance S, the n3 n matrix of pairwise LD (r) values. A vector
of n independent, standard, normally distributed random
variables is ﬁrst generated and then multiplied by the Cho-
lesky decomposition matrix of S – that is, the n 3 n lower
triangular matrix C, such that CCT ¼ S. The new random
vector, Z ¼ ðz1,z2.znÞ, will have a multivariate normal
distribution, Z  Nnð0,
PÞ. Z is then transformed into
a vector of correlated chi-squared 1 df variables,
Q ¼ ðq1,q2.qnÞ, qi ¼ z2i . The simulated gene-based test
statistic is then the sum of all (or a predeﬁned subset) of
the elements of Q and will have the same approximate
distribution as our observed gene-based test statistic under
the null hypothesis. A large number of multivariate
normal vectors are simulated, and the empirical gene-
based p value is the proportion of simulated test statistics
that exceed the observed gene-based test statistic.
We have implemented VEGAS in both an easy-to-use
web-interface or as a downloadable application for Linux
and Unix. The only user inputs required are a text ﬁle con-
sisting of two columns: SNP rs-name and association p
value, along with speciﬁcation of the reference population
(CEU, CHB and JPT, or YRI). The downloadable version
also allows the use of custom individual genotypes if avail-
able, as well as speciﬁcation of gene boundaries. Pairwise
LD correlation matrices are calculated in PLINK. The R
corpcor package is used to correct for non-positive deﬁnite
correlation matrices,12 and multivariate normal random
vectors are simulated with the mvtnorm package.13
The number of simulations per gene is determined adap-
tively. In the ﬁrst stage, 103 simulations will be performed.140 The American Journal of Human Genetics 87, 139–145, July 9, 20If the resulting empirical p value is less than 0.1, 104 simu-
lations will be performed. If the empirical p value from 104
simulations is less than 0.001, the program will perform
106 simulations. At each stage, the simulations are mutu-
ally exclusive. For computational reasons, if the empirical
p value is 0, then no more simulations will be performed.
An empirical p value of 0 from 106 simulations can be in-
terpreted as p < 106, which exceeds a Bonferroni-cor-
rected threshold of p < 2.8 3 106 (z0.05/17,787; this
threshold is likely to be conservative given the overlap
between genes). The user may select whether to perform
the gene-based test on the full set of SNPs within a gene,
a speciﬁed percentage of the most signiﬁcant SNPs, or
just the single most signiﬁcant SNP. Because the program
depends upon the output from other programs, it is impor-
tant to take correct GWAS quality-control measures to
account for issues such as population stratiﬁcation or pool-
ing errors before using VEGAS.
Using a test with permutations as the ‘‘gold standard,’’
we compared the results from VEGAS to those from the
PLINK set-based test8 with permutations (with parameters
--set-p1 --set-r21 --maf 0.01) on a GWAS for height in 3,611
unrelated Australian individuals drawn from community-
based twin studies conducted from 1980 to 2004. Several
recent genetic studies of other traits,14–16 have used these
samples and have described genotype and phenotype
data cleaning. In brief, height was corrected for age and
sex before being converted to standard z scores. PLINK
was used for performing genome-wide association, from
which the results were used in our method. For a given set
of SNPs, the PLINK set-based test initially performs a stan-
dard association test and then uses the average association
test statistic across these SNPs as the ‘‘set-based’’ test
statistic (VEGAS uses the sum rather than average; the
two methods are equivalent in calculations of empirical p
values). Then, for the permutation procedure, the pheno-
types are randomly shufﬂed among individuals, and the
process is repeated several thousand times, from which
an empirical p value is obtained. Because of computational
limitations, we only performed the PLINK set-based test on
413 genes on chromosome 22 with 104 permutations each.
To see how both tests deal with more signiﬁcant genes, we
performed 106–107 permutations on seven additional
genes. These genes were chosen on the basis of having p
values < 103 when VEGAS was applied across all chromo-
somes. across all chromosomes. The results from both tests
are shown in Figure 1, which compares the corresponding
log10(p value)s from the PLINK set-based test and VEGAS
for 420 genes. For the majority of genes, both methods
produced very similar results. Correlation between the
p values was very high (Pearson r ¼ 0.999), as was that
between the rankings (Spearman r ¼ 0.998). Thus, in addi-
tion to being agnostic toward GWAS design, a major
advantage of our method over permutations is speed.
The PLINK set-based test on our computer took ~12 hr to
compute the 413 chromosome 22 genes plus 2 days for
the seven additional genes. In contrast, our approach10
Figure 1. Comparison of the log10(p value)s from the PLINK
Set-Based Test and VEGAS on a GWAS of Height in 3,611
Individuals
The PLINK set-based test was performed on 413 genes on chromo-
some 22 with 104 permutations (circles) and on seven genes on
other chromosomes; these were selected on the basis of having
the smallest p values from the VEGAS analysis, at 106 to 107
permutations (triangles). The p values from VEGAS were obtained
by running 103 to 107 multivariate normal simulations per gene.
The straight diagonal line indicates a 1:1 relationship.
Figure 2. Comparison of the log10(p value)s from Permuta-
tions and VEGAS When Only the Single Best SNP from Each
Gene Is Considered
Results are based on a GWAS of height in 3611 individuals. Permu-
tations were performed on 413 genes on chromosome 22 with 103
permutations and on seven additional genes with 105–106 permu-
tations. The p values from VEGAS were obtained from 103–106
multivariate normal simulations per gene. The straight diagonal
line indicates a 1:1 relationship.with 103 to 106 simulations per gene computed the same
set of genes in less than thirty minutes.
Weselectedninenonoverlappinggenesof various sizes on
chromosome 22 to further investigate the type I error rate of
our method compared to those from permutations. The
previous height data were permuted 1000 times. VEGAS
and the PLINK set-based test were applied to the association
results of each permutation for each of the genes. The
comparison of the p values for each of the nine genes is
shown in Figure S1. Overall, there does not appear to be
anymajorbias involvedwithVEGAS.Nevertheless, it should
benoted that ourmethodwill produce spurious results if the
incorrect reference population, and hence LD structure, is
used. Biases toward smaller p values will occur if the refer-
ence population is older than the study population, and
larger p values will occur in the opposite situation. When
the same 420 genes and 3611 Australian individuals were
used, running VEGAS with the HapMap CEU population
as the reference produced results comparable to those from
permutation (Figure S2A), whereas using the HapMap YRI
population produced signiﬁcant biases toward smaller
p values (Figure S2B). Slight biases might also potentially
occur for genes with a non-positive deﬁnite LD correlation
matrix. In our dataset, this was a property of ~80% of genes,
inhibiting the direct use of Cholesky decomposition. For
these genes, the nearest positive semideﬁnite matrix is esti-
matedwith the R corpcor package.12,17Matrices that require
a large adjustment might explain some of the discrepancyThe Abetween VEGAS and permutations, although as seen in
Figure 1, this does not appear to have a major effect.
Under some genetic architectures, amore powerful gene-
basedmethodmay be to consider only themost signiﬁcant
SNP in a gene rather than the full set of SNPs and then
correct this SNP’s association p value for gene size and other
possible confounders. Our approach can readily be applied
to this situation. For a genewithnSNPs, recall the simulated
vector of n correlated chi-squared 1 df variables,
Q ¼ ðq1,q2.qnÞ. For the ‘‘Top-SNP’’ method, we deﬁne
Qmax as the simulated test statistic of themaximumelement
ofQ. Then, by simulating a large number ofQmax test statis-
tics, the empirical gene-based p value is the proportion of
simulated Qmax test statistics that exceed the observed test
statistic of the most signiﬁcant SNP in the gene.
Using the same 420 genes as in our previous analysis
with the full set of SNPs, we compared the VEGAS Top-
SNP method and permutations (Figure 2). Note that in
this case, we ran our own permutations by using R rather
than the PLINK set-based test because the two methods
are not equivalent. As with the test considering the full
set of SNPs, VEGAS produces results very similar to those
from permutations. Correlation between the p values was
very high (Pearson r ¼ 0.996), as was that between the
rankings (Spearman r ¼ 0.996).
Our method of using the full set of SNPs per gene was
applied to two situations where permutation tests are not
applicable: a family-based GWAS for height, where permu-
tation cannot account for phenotypic correlation betweenmerican Journal of Human Genetics 87, 139–145, July 9, 2010 141
Table 1. VEGAS Results for the 15 Most Significant Genes from a Family-Based GWAS for Height in 11,536 Individuals
Chromosome Gene Number of SNPs Start Position Stop Position Test Statistic p Value Best SNP SNP p Value
4 HHIPa 26 145786622 145879331 263.505 106 rs1812175 1.06 3 109
6 GPR126a 23 142664748 142809096 169.912 5 3 106 rs6570507 2.16 3 107
8 CHCHD7a 4 57286868 57293730 31.82 3.2 3 105 rs7833986 2.20 3 104
6 HMGA1a 6 34312627 34321986 38.934 8.4 3 105 rs1776897 6.71 3 106
15 ADAMTSL3a 85 82113841 82499597 344.52 1.34 3 104 rs7183263 3.89 3 107
4 LCORLa 30 17453940 17632474 222.748 1.38 3 104 rs6817306 7.63 3 106
20 GDF5a 10 33484562 33489441 81.199 1.78 3 104 rs4911494 1.39 3 104
12 HMGA2a 34 64504506 64646338 147.824 3.00 3 104 rs8756 4.263107
1 MFAP2 15 17173585 17180668 76.961 3.71 3 104 rs11203280 6.03 3 104
17 C17orf78 5 32807097 32823775 27.012 5.31 3 104 rs8067120 1.80 3 103
6 HIST1H3Ga 16 26379124 26379591 86.062 5.77 3 104 rs10946808 2.48 3 105
2 NMUR1 18 232096114 232103426 102.955 6.05 3 104 rs1434519 3.29 3 105
4 ADH5 26 100211152 100228954 142.218 8.01 3 104 rs1042364 2.45 3 104
8 SPATC1 8 145158594 145174003 58.172 8.30 3 104 rs3936211 7.35 3 104
2 EMX1 13 72998111 73015528 60.278 9.62 3 104 rs10183113 3.71 3 106
a These genes have been implicated in previous GWAS of height.22 The signal in HIST1H3G is driven by a variant previously implicated in the neighboring
HIST1H1G.family members, and a DNA-pooling GWAS for melanoma
(MIM 155600), where individual genotype information is
not available. For height, we included an extra 7,935 rela-
tives of those in our original GWAS of 3,611 unrelated indi-
viduals. These consisted of parents, offspring, siblings,
twins, and other family members, all typed with the
same SNP chip as the unrelated individuals used in the ﬁrst
calculation. The results of the family-based association
analysis were previously published in Liu, et al.18 Table 1
lists the 15 most signiﬁcant height-associated genes
obtained from VEGAS. One gene, the previously impli-
cated HHIP (MIM 606178; p ¼ 1 3 106),19–21 exceeded
a Bonferroni corrected threshold of p < 2.8 3 106. Over-
all, nine of the top 15 genes have been previously impli-
cated in published GWAS of height at genome-wide signif-
icance.22 It remains to be seen whether any of the
remaining genes play a role in height. The gene NMUR1
(MIM 604153; p ¼ 6.05 3 104) is a G-protein-coupled
receptor and is also involved in neuropeptide signaling,
similar to the previously implicated GPR126 (MIM
612243; p ¼ 5 3 106). Height might also be mediated
by MFAP2 (MIM 156790; p ¼ 3.71 3 104) through its
role as a glycoprotein component of connective-tissue
microﬁbrils,23 for which normal connective-tissue devel-
opment is essential for height growth. Mutations in other
microﬁbril components have been linked to Marfan
syndrome (MIM 154700), a genetic disorder characterized
by skeletal overgrowth.24 These results suggest that despite
having a relatively small sample size for a GWAS for height,
the gene-based test has the potential to identify novel
genes. In a two-stage GWAS, the most signiﬁcant genes142 The American Journal of Human Genetics 87, 139–145, July 9, 20may also be used as a basis for selecting SNPs for replication
samples.
For melanoma, the gene-based test was performed on
the results from a GWAS that used pooled DNA in 1354
melanoma cases and 1291 controls. The sample was origi-
nally part of a larger previously published GWAS for mela-
noma,25 and pooling and association methods are
described in that study. This study was performed with
the approval of the appropriate ethics committee and
with informed consent from all participants.
As for height, the results from the gene-based test are
consistent with our current understanding of the genetics
of melanoma (Table 2). Overall, all of the top 15 genes are
in regions known to harbor melanoma-susceptibility
genes. Seven genes identiﬁed are located on 20q11.22,
the region originally implicated by Brown et al.25 and con-
taining the skin pigmentation gene ASIP (MIM 600201);
these include MAP1LC3A (MIM 601242; p < 106), PIGU
(MIM 608528; p ¼ 2 3 106), DYNLRB1 (MIM 607167;
p ¼ 7 3 106), TP53INP2 (p ¼ 4.7 3 105), and NCOA6
(MIM 605299; p ¼ 1.38 3 104). ASIP itself, however,
was nonsigniﬁcant (p ¼ 0.116). Given the size of this asso-
ciated region, it could be the case that a distant enhancer
rather than nonsynonymous or proximal regulatory
elements is driving the association with ASIP. Similarly,
a large number of associated genes are also located on
16q24.3; the most signiﬁcant of these genes was DEF8
(p ¼ 4 3 105). Given that DEF8 lies ~30 kb downstream
of the known melanoma-susceptibility gene, MC1R (MIM
155555), it is likely that this signal is driven by variants
in and around MC1R, which was only nominally10
Table 2. VEGAS Results for the 15 Most Significant Genes from a DNA-Pooling GWAS for Melanoma in 1354 Cases and 1291 Controls
Chromosome Gene Number of SNPs Start Position Stop Position Test Statistic p Value Best SNP SNP p Value
20 MAP1LC3A 59 32598352 32611810 762.618 <106 rs910873 1.00 3 1016
20 PIGU 93 32612006 32728750 964.294 2 3 106 rs910873 1.00 3 1016
15 MYEF2 25 46218920 46257850 50.865 4 3 106 rs2470102 4.18 3 104
20 DYNLRB1 58 32567864 32592423 548.265 7 3 106 rs910873 1.00 3 1016
20 SNTA1 39 31459423 31495359 242.906 9 3 106 rs291695 6.60 3 1011
16 DEF8 73 88542651 88561968 318.251 4.0 3 105 rs1805007 3.33 3 1016
20 TP53INP2 44 32755808 32764898 312.611 4.7 3 105 rs4417778 5.35 3 109
20 NCOA6 81 32766238 32877094 563.953 1.38 3 104 rs4911442 2.71 3 1010
20 CDK5RAP1 55 31410305 31452998 260.851 1.53 3 104 rs291695 6.60 3 1011
5 RXFP3 48 33972247 33974099 138.421 1.95 3 104 rs35389 1.31 3 108
16 C16orf55 49 88251710 88265176 244.276 3.12 3 104 rs258322 1.34 3 107
16 MGC16385 59 88563701 88566443 218.033 3.99 3 104 rs8049897 9.74 3 107
16 DPEP1 58 88207216 88232340 248.214 4.54 3 104 rs12918773 4.47 3 107
16 CHMP1A 52 88238344 88251630 248.105 4.60 3 104 rs258322 1.34 3 107
16 SPG7 73 88102305 88151675 370.214 4.66 3 104 rs4785686 2.76 3 107signiﬁcant (p ¼ 1.30 3 103), rather than DEF8 itself. Like-
wise, the gene RXFP3 (p ¼ 1.95 3 104) is adjacent to
SLC45A2 (MIM 606202; p ¼ 8.91 3 103), a known mela-
noma-susceptibility gene, and MYEF2 (p ¼ 4 3 106) is
adjacent to SLC24A5 (MIM 609802; p ¼ 2.34 3 103),
a gene associated with skin pigmentation.
Although VEGAS was able to produce results equivalent
to those obtained through permutations at a fraction of
the time taken, as well as replicate several known height-
and melanoma-associated genes, there are several situa-
tions in which use of the gene-based test is limited. The
effectiveness of VEGAS, along with other gene-based
methods, is determined by the underlying genetic archi-
tecture of the gene and phenotype of interest. Although
gene-based methods are more powerful than single-marker
analysis for identifying signiﬁcant genes with multiple
causal variants, the converse is also true. If a gene contains
only one causal variant, then the inclusion of a large
number of nonsigniﬁcant markers into the gene-based
test will dilute this gene’s signiﬁcance. The correct genetic
model to use is seldom known in advance, although our
method can be performed on a speciﬁed subset of markers
or just the single most signiﬁcant marker rather than all
markers in a gene. Similarly, the use of 5 50 kb to deﬁne
gene boundaries is an arbitrary choice. Large boundaries
mean that somemarkers are included inmultiple genes, re-
sulting in a situation similar to our results for melanoma,
where it may be difﬁcult to pinpoint the causal gene
when multiple adjacent genes are statistically signiﬁcant.
Specifying stringent boundaries, however, may not fully
capture regulatory regions or those SNPs in high LD with
variants in the gene. Moreover, given that the majority
of SNPs so far identiﬁed in GWAS are found in nongenicThe Aregions,26 these SNPs would not be included in any gene-
centric analysis at all. For these reasons, gene-based
methods should not be seen as a replacement for tradi-
tional single-marker association studies but rather should
be seen as a complement to GWAS and an essential step
for network- and pathway-based approaches. We offer
our gene-based test not as a deﬁnitive solution to the
problem but also as one tool in the complex-trait geneti-
cist’s toolbox for post-GWAS analysis.Supplemental Data
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